Article info

Download PDFPDF

517 Splenic tumor-reactive CD8+ T cells are endowed with a unique potential for expansion and are the dominant source of systemic anti-tumor immunity after ICB therapy
Free

Authors

Citation

Horton B, Morgan D, Love J, et al
517 Splenic tumor-reactive CD8+ T cells are endowed with a unique potential for expansion and are the dominant source of systemic anti-tumor immunity after ICB therapy

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.